ArefAl-KaliMD

PubMed

• 129 citations
  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
  Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R. Baer, Mikkael A. Sekeres
  The Lancet. Oncology. 2016-04-01
• 1 citations
  PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
  Ayalew Tefferi, Saubia Fathima, Ali Khalid A Alsugair, Fnu Aperna, Anuya Natu
  American Journal of Hematology. 2024-12-01
• 4 citations
  TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
  Mark Gurney, Patricia T Greipp, Troy Gliem, Ryan Knudson, Aref Al-Kali
  Leukemia Research. 2023-11-01

Journal Articles

• Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed with Chronic Myelomonocytic Leukemia (CMML): A Single Institution Experience  
  A Alsahlawi, H Alkhateeb, M Patnaik, K Begna, M Elliott, W Hogan, M Litzow, A Al-Kali, Clinical Lymphoma, Myeloma and Leukemia, 6/10/2014
• Toxoplasmosis in Patients with hematologic Malignancies  
  A Chintakuntlawar, M Kidd, A Al-Kali, W Wilson, CA Thompson, Leuk Lymphoma, 5/31/2014
• Revised Assessment of Response and Long-term Discontinuation Rates among 111 Patients with Myelofibrosis Treated with Momelotinib and Ruxolitinib  
  Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A, Leukemia, 1/1/2014
• Genetic Determinants of Response and Survival in Momelotinib Treated Patients with Myelofibrosis  
  Pardanani A, Abdelrahman RA, Finke C, Lasho T, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Tefferi A, Leukemia, 1/1/2014
• Prognostic Impact of RAS Mutations in Patients with Myelodysplastic Syndrome  
  A Al-Kali, A Quintas-Cardama, R Luthra, C Bueso-Ramos, S Pierce, T Kadia, G Borthakur, Z Estrov, E Jabbour, S Faderl, F Ravandi, J Cortes, A Tefferi, H Kantarjian, G G..., Am J Hematol, 5/1/2013
• Comparison of Complication Rates of Hickman Catheters versus Peripherally Inserted Central Catheters in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy  
  M Lim, A Al-Kali, A Ashrani, K Begna, M Elliott, W Hogan, C Hook, S Kaufmann, L Letendre, M Litzow, M Patnaik, A Pardanani, A Tefferi, A Wolanskyj, D Grill, R Pruthi, Leukemia & Lymphoma, 11/19/2012
• Hypocellular Acute Myeloid Leukemia in Adults: Clinical Outcome Analysis of 123 Patients  
  A Al-Kali, konoplev S, Lin E, Kadia TM, Faderl S, Ravandi F, Ayoubi M, Cortes J, Kantarjian H, G Borthakur, Haematologica, 1/1/2012
• Therapy-rlated Acute Promyelocytic Leukemia (T-APL): Observations Relating to APL Pathogenesis and Therapy  
  M Elliott, L Letendre, A Tefferi, W Hogan, C Hook, R Pruthi, S Kaufmann, A Pardanani, K begna, A Ashrani, A Wolanskyj, A Al-Kali, M Litzow, Eur J Haematol, 1/1/2012
• IPSS-independent Prognostic Value of Plasma CXCL 10, IL-7, and IL-6 Levels in Myelodysplastic Sindromes  
  A Paradanani, C Finke, TL Lasho, A Al-Kali, KH Begna, CA Hanson, A Tefferi, Leukemia, 1/1/2012
• Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leu...  
  A Al-Kali, D Jones, J Cortes, S Faderl, X Ao, G Garcia-Manero, G Borthakur, M Konopleva, M Brandt, M Andreef, H Kantarjian, F Ravandi, Clinical Lymphoma, Myeloma, and Leukemia, 1/1/2011
• Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts For Restoring Response with Sequent...  
  A Al-Kali, H Kantarjian, J Shan, W Wierda, G Borthakur, Z Estrov, Srdan Verstovsek, S O'brien, J Cortes, Cancer, 1/1/2011
• Renal Cell Carcinoma with Cutanous Metastases Literature Review  
  N Srinivasan, S Rathi, A Al-Kali, W Ahmad, Am J Med Sci, 5/1/2010
• Competing Cell Clones in Myelproliferative Neoplasm  
  A Al-Kali and S Verstovsek, H Kantarjian, R Luthra, J Cortes, Blood, 1/1/2010
• Forodesine: Review of Preclinical and Clinical Data  
  A Al-Kali, Micheal Keating, Farhad Ravandi, Future Oncology, 1/1/2010
• Critical Appraisal of the Role of Rituximabin the Treatment of Patients with Previously Untreated or Teated Chronic Lymphocytic Leukemia (CLL)  
  A Al-Kali, W Wierda, M Keating, S O'Brien, Blood Medicine, 1/1/2010
• The Role of Monoclonal Antibodies in the Management of Leukemia  
  A Al-Ameri, M Cherry, A Al-Kali, A Ferrajoli, Pharmaceuticals, 1/1/2010
• An AML Case Mistreated as CLL: What Do We Know About t(4,12)(q12;p13)?  
  A Al-Kali, M Cherry, K Kimmell, J Holter, W Kern, H Ozer, G Selby, Cancer Cytogenetics, 1/1/2010
• Tumor Lysis Syndrome after Staring Gleevec in a Patient with Chronic Myelogenous Leukemia  
  A Al-Kali, S Farooq, A Tfayli, Journal of Clinical Pharmacy and Therapeutics, 4/1/2009
• Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases  
  MJ Overman, D Fogelam, A Al-Kali, CH Crane, D Evans, EK Abdalla, P Pisters, S Kopetz, C Eng, RA Wolff, Clinical Colorectal Cancer, 9/1/2008
• Non-Autoimmune Hemolytic Anemia with Clostridium Ramosum Bacteremia  
  A Al-Kali, A Oswal, A Tfayli, Clinical Medicine- Case Reports, 5/1/2008
• First-Cycle CSF Use in Breast Cancer and NHL: Guidelines and Recommendations  
  A Al-Kali, H Ozer, The Oncology, 12/1/2006
• Join now to see all

Books/Book Chapters

• Chronic Myeloid Leukemia: From Daily Management to Complicated Issues 
  Chapter: Chapter IX: Management of Chornic Myeloid Leukemia (CML): Accelerated Phase (AP) 
  Nova Science Publishers2014
• Chronic Myeloid Leukemia: From Daily Management to Complicated Issues 
  Chapter: Chapter X: Management of Chornic Myeloid Leukemia (CML): Blast Phase (BP) 
  Nova Science Publishers2014

Abstracts/Posters

• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytos...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...
  Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• NPM1+/FLT3- Patients with Acute Myeloid Leukemia (AML) have Excellent Clinical Outcome Independent of Age When Treated with Cytotoxic Chemotherapy: Mayo Clinic Experience
  M Hefazi Torghabeh, M Siddiqui, M Patnaik, A Wolanskyj, D Zblewski, M Elliott, W Hogan, M Litzow, A Al-Kali, ASH, 1/1/2014
• Clinical Outcome of Patient Diagnosed with Myelodysplastic Syndrome-unclassifiable (MDS-U): Single Center Experience
  F Baidoun, D Chen, H Alkhateeb, D Zblewski, M Elliott, W Hogan, M Litzow, A Al-Kali, ASH, 1/1/2014
• Signfiicance Oand Clinical Impact of CD117 Expression in Newly Diagnosed AML
  H Alkhateeb, M Litzow, S Hashmi, W Hogan, M Patnaik, M Elliott, D Chen, A Al-Kali, ASCO, 1/1/2014
• Body Mass Index Impact on Acute Myeloid Leukemia (AML) Outcomes
  A Elkhanany, N Keane, S Hashmi, K Begna, R Pruthi, WJ Hogan, MR Litzow, A Al-Kali, ASCO, 1/1/2013
• A Novel Prognostic Model to Predict Relapse after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
  SS Kenderian, MR Litzow, A Al-Kali, DA Gastineau, S Hashmi, WJ Hogan, MM Patnaik, ASH, 1/1/2013
• Erlotinib Is Not Effective in Patients (Pts) With JAK-2V617F Positive Polycythemia Vera
  M Cherry, M Khawandanah, ZJ Zhao, SA Srour, H Ozer, G Selby, B Ghabach, A Al-Kali, ASH, 1/1/2013
• Hepatic and Metabolic Complications in Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Asparaginase-containing Combination Chemotherapy: A Single C...
  J Baretto, KB McCullough, CS Peskey, L Letendre, W Hogan, A Al-Kali, MR Litzow, MM Patnaik, ASH, 1/1/2013
• Retrospective Comparison of Survival and Leukemic Transformation in Myelofibrosis Patients Treated with Ruxolitinib versus Momelotinib versus Fedratinib versus Pomalid...
  A Pardanani, RA Abdelrahman, K Begna, D Zblewski, A Al-Kali, MM Patnaik, W Hogan, CA Hanson, MR Litzow, A Tefferi, ASH, 1/1/2013
• Monosomal Karyotype Predicts Adverse Prognosis in Patients with Chronic Myelomonocytic Leukemia
  AK Alsahlawi, H Alkhateeb, MM Patnaik, K Begna, M Elliott, W Hogan, RP Ketterling, MR Litzow, A Al-Kali, ASH, 1/1/2013
• Thromboembolic and Hemorrhagic Complications in Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Asparaginase-containing Combination Chemotherapy: A...
  J Barreto, KB Mccullough, CS Peskey, M Elliott, DA Gastineau, A Al-Kali, L Letendre, W Hogan, MR Litzow, MM Patnaik, ASH, 1/1/2013
• Clonal Evolution as Determined by Sequential Bone Marrow Karyotype Analysis during JAK Inhibitor Therapy for Myelofibrosis: Impact on Treatment Response and Overall an...
  R Abdelrahman, K Begna, D Zblewski, A Al-Kali, MM Patnaik, W Hogan, RA Knudson, RP Ketterling, CA Hanson, MR Litzow, A Tefferi, A Pardanani, ASH, 1/1/2013
• Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response in JAK Inhibitor Treated Myelofibrosis Patients
  A Pardanani, R Abdelrahman, K Begna, D Zblewski, A Al-Kali, MM Patnaik, W Hogan, TL Lasho, C Finke, CA Hanson, MR Litzow, A Tefferi, ASH, 1/1/2013
• Oral Rigosertib (ON01910.Na) Treatment Produces an Encouraging Rate of Transfusion Independence in Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methy...
  A Raza, B Tycko, S Lee, N Galili, A Ali, A Eisenberger, J Mears, A Al-Kali, R Tibes, G Spitzer, F Wilhelm, S Mukherjee, ASH, 1/1/2013
• Join now to see all

Lectures

• A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis. 
  2019 ASCO Annual Meeting - 6/1/2019
• A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematological Emergencies in the ICU 
  8/19/2014
• Hem Emergencies 
  7/8/2014
• 9th Annual Mayo Clinic Hematology Review 
  Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 1/28/2012
• ASH Updates in MDS 
  1/28/2011
• CMML: Review and Update 
  Mayo Clinic, Rochester, MN - 9/2/2010
• Genetics and Biotherapy Update in Leukemia 
  7/5/2010
• New Concepts in Myeloid Malignancies 
  Mayo Clinic, Rochester, MN - 3/4/2010
• Join now to see all